Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes
Preprint
Abstract
In 579 COVID patients’ samples collected between March and July of 2020, we examined the effects of non-synonymous mutations harbored by the circulating B.1.1.7 strain on linear antibody epitope signal for spike glycoprotein and nucleoprotein. At the antigen level, the mutations only substantially reduced signal in 0.5% of the population. Although some epitope mutations reduce measured signal in up to 6% of the population, these are not the dominant epitopes for their antigens. Given dominant epitope patterns observed, our data suggest that the mutations would not result in immune evasion of linear epitopes for a large majority of these COVID patients.Keywords
This publication has 9 references indexed in Scilit:
- Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescenceScience Immunology, 2020
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesNew England Journal of Medicine, 2020
- High-resolution mapping and characterization of epitopes in COVID-19 patientsmedRxiv, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportNew England Journal of Medicine, 2020
- Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort studyThe Lancet, 2020
- Protein-based Immunome Wide Association Studies (PIWAS) for the discovery of significant disease-associated antigensbioRxiv, 2020
- SLIM: Simultaneous Logic-in-Memory Computing Exploiting Bilayer Analog OxRAM DevicesScientific Reports, 2020
- UniProt: the universal protein knowledgebaseNucleic Acids Research, 2016
- Identification of disease-specific motifs in the antibody specificity repertoire via next-generation sequencingScientific Reports, 2016